AIM
BLUE

Aigen Investment Management’s bluebird bio BLUE Stock Holding History

Aigen Investment Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-565
Closed -$34.4K – 806
2023
Q3 		$34.4K Buy
+565
New +$39.7K 0.01% 780

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Aigen Investment Management's BLUE Position: Q4 2023 in Review

Aigen Investment Management sold out of bluebird bio (BLUE) in Q4 2023, closing a stake of 565 shares — an estimated $34.4K sold.

Aigen Investment Management first reported a position in BLUE in Q3 2023 and held it in 1 quarter. The position peaked at $34.4K in Q3 2023. 187 funds tracked by Wall St. Rank hold BLUE as of Q4 2023.

  • Aigen Investment Management reported no remaining bluebird bio position as of Q4 2023 after selling out during the quarter.
  • Aigen Investment Management sold 565 bluebird bio shares in Q4 2023, an estimated $34.4K.
  • Aigen Investment Management first reported a position in bluebird bio in Q3 2023 and held it in 1 quarter.
  • Aigen Investment Management's bluebird bio position peaked at $34.4K in Q3 2023.
  • 187 funds tracked by Wall St. Rank held bluebird bio as of Q4 2023.

Based on Aigen Investment Management's 13F filing for Q4 2023, filed 9 Feb 2024.